A New Day Coming for U.S. Biotech

After the sweeping results of the election on November 5, 2024, all sectors of business are evaluating potential regulatory impacts directly applicable to them. Certainly in the medical products and biotech industries, there is much interest in who will be named to head Health and Human Services (HHS), Food and Drug Administration (FDA) and Center for Medicare and Medicaid Services (CMS). But were the most impactful announcements already made? The new Department of Government Efficiency might end up having more impact on the medical products and biotech space than the heads of HHS, FDA, and CMS combined. Many stakeholders have suffered through inefficiencies at those agencies, and if anything is on the chopping block now it is inefficiency. Setting inefficiencies aside might (hopefully) create even more opportunities for U.S. Biotech to work towards being global leader in the biotech and medical products industry. A new day might be coming, and there might be opportunities we didn’t see coming.